Active Broker’s Concerns In Focus: DigitalGlobe, Inc. (NYSE:DGI), Wabash National Corporation (NYSE:WNC)

DigitalGlobe, Inc. (NYSE:DGI) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -8.22% to $31.25. MacDonald, Dettwiler and Associates Ltd. (MDA) and DigitalGlobe, Inc. (DGI) reported a merger contract, pursuant to which MDA will acquire DigitalGlobe for $35.00 per share in a combination of cash and stock.

The transaction values DigitalGlobe at an equity value of approximately C$3.1 billion or US$2.4 billion, and an enterprise value of C$4.7 billion or US$3.6 billion, including assumption of DigitalGlobe’s C$1.6 billion or US$1.2 billion, in net debt. Each DigitalGlobe common share will be exchanged for US$17.50 in cash and 0.3132 MDA common shares, representing a per share value of US$17.50.

MDA will apply to list its shares on the NYSE in addition to the TSX. Upon completion of the transaction, the combined company will continue to execute its U.S. Access Plan strategy. This will include further reorganization of all or part of the combined Company’s corporate and operating structure to ensure that the ultimate parent of DigitalGlobe is incorporated in the U.S. by the end of 2019.

Lance, president and CEO of MDA and president and CEO of SSL MDA Holdings, will lead the combined company. The combined company will have approximately 4,600 employees in the United States and will continue to employ more than 1,800 in Canada. The share price of DGI attracts active investors, as stock price of week volatility recorded 7.42%. The stock is going forward to its 52-week low with 134.61% and lagging behind from its 52-week high price with -13.07%.

Wabash National Corporation (NYSE:WNC) [Trend Analysis] moved up reacts as active mover, shares an increase 1.76% to traded at $20.85 and the percentage gap between open changing to regular change was 0.34%. Wabash National Corporation (WNC) reported that its board of directors has authorized the Company to repurchase up to an additional $100 million of its common stock over the next two years. This authorization is an increase to the existing $100 million repurchase program previously authorized in February 2016 and of which approximately $15 million was accessible as of February 23, 2017.

Stock repurchases under this program may be made in the open market or in private transactions at times and in amounts determined by the Company. The Company, at its sole discretion, may limit or terminate the stock repurchase program at any time based on market conditions, liquidity needs or other factors.

The program is intended to enhance shareholder value by reducing the overall number of outstanding shares, including by offsetting dilution resulting from stock-based compensation programs. The firm’s current ratio calculated as 2.90 for the most recent quarter. The firm past twelve months price to sales ratio was 0.69 and price to cash ratio remained 7.77. As far as the returns are concern, the return on equity was recorded as 25.10% and return on investment was 19.20% while its return on asset stayed at 12.40%. The firm has total debt to equity ratio measured as 0.50.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *